Neoadjuvant Chemotherapy Plus Surgery Versus Surgery First For Elderly Gastric Cancer Patients

Launched by BIRENDRA KUMAR SAH · Dec 17, 2020

Keywords

ClinConnect Summary

This clinical trial is studying the best way to treat elderly patients with locally advanced gastric cancer, which is a type of stomach cancer. Researchers want to find out if giving chemotherapy (a treatment that uses powerful drugs to kill cancer cells) before surgery is more effective than just doing surgery first. This chemotherapy regimen is known as modified SOX. The trial aims to see if this approach is safe and beneficial for older patients facing this illness.

To be eligible for the trial, participants need to have a specific type of stomach cancer that has not caused a blockage and is at an advanced stage (stage III). They should be in reasonably good health, meaning they can handle both chemotherapy and surgery without major health issues. However, those with severe heart problems, other uncontrolled diseases, or prior treatments for cancer won't be included. If someone joins the trial, they can expect to receive the chemotherapy before their surgery and will be monitored closely throughout the process. This trial is not yet recruiting participants, so more details will be available as it gets underway.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histology confirmed non-obstructive adenocarcinoma of the stomach or esophagogastric junction.
• • Clinical stage: cTNM: stage III
• • Performance status: Eastern Cooperative Oncology Group ECOG ≤ 2 (normal to symptomatic but in bed less than half the day)
• • Clinically fit for systemic chemotherapy and gastric cancer surgery, i.e. adequate renal, hepatic, hematologic, and pulmonary function.
• • Written informed consent
• Exclusion Criteria:
• • Clinically unfit for systemic chemotherapy and gastric cancer surgery, i.e. uncontrolled cardiac disease, or other clinically significant uncontrolled comorbidities, unable to undergo general anesthesia
• • Distant metastases (including retroperitoneal lymph node)
• • Locally advanced inoperable disease (Clinical assessment)
• • Relapse of gastric cancer
• • Malignant secondary disease
• • Prior chemo or radiotherapy
• • Inclusion in another clinical trial
• • Known contraindications or hypersensitivity for planned chemotherapy